Skyrizi 150 MG/ML penml
Ended Awarded Last action
- Contract number
- SPE2DR26FR12Q
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $44,727
Award facts
- Contract value 100% obligated
- $44,727.29 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $44,727.29 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML (risankizumab), a prescription medication used to treat inflammatory conditions such as psoriasis and Crohn's disease. The contract, awarded on January 22, 2026, with an ultimate completion date of January 23, 2026, reflects a firm fixed-price arrangement with no set-aside designation, indicating competitive award based on open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order is issued under the company's parent organization, Cencora, Inc. (formerly doing business as AmerisourceBergen), which holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 31, 2031.
AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems through this IDC vehicle, which enables supply of a comprehensive range of pharmaceutical products, specialty medications, vaccines, and medical supplies to support global military healthcare programs. The company's federal contract portfolio demonstrates extensive capability in fulfilling government procurement requirements for diverse therapeutic medications including oncology drugs, diabetes treatments, and neurological medications. This particular delivery order represents routine pharmaceutical supply fulfillment under the broader strategic vehicle that allows the Defense Logistics Agency to leverage flexible contracting mechanisms for essential medical commodities across the Department of Defense healthcare enterprise.
Quick answers
Who was awarded contract SPE2DR26FR12Q?
SPE2DR26FR12Q was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FR12Q worth?
The government has obligated $44,727 on SPE2DR26FR12Q.
Is contract SPE2DR26FR12Q an order under another contract?
Yes. SPE2DR26FR12Q is a delivery order under SPE2DR25D2003, an indefinite delivery contract.
Was contract SPE2DR26FR12Q competed?
The extent of competition for SPE2DR26FR12Q was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award